Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 14;14(6):e1006990.
doi: 10.1371/journal.ppat.1006990. eCollection 2018 Jun.

CRISPR-Cas antimicrobials: Challenges and future prospects

Elizabeth Pursey  1   2 , David Sünderhauf  1   2 , William H Gaze  2 , Edze R Westra  1 , Stineke van Houte  1
Affiliations

CRISPR-Cas antimicrobials: Challenges and future prospects

Elizabeth Pursey et al. PLoS Pathog. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Challenges associated with CRISPR-Cas antimicrobials and potential routes to overcome them.
A summary of the obstacles associated with using CRISPR-Cas–based antimicrobials in complex environmental populations of bacteria is shown. These include ensuring effective delivery of constructs (top left), routes of resistance evolution to these novel antimicrobials (top right), the species diversity and spatial complexity of bacterial communities (bottom left), and uncertainty in usage guidelines and stakeholder support (bottom right). AMR, antimicrobial resistance; CRISPR-Cas, clustered regularly interspaced short palindromic repeats-CRISPR–associated.
See this image and copyright information in PMC

References

    1. Årdal C, Baraldi E, Ciabuschi F, Outterson K, Rex JH, Piddock LJV, et al. To the G20: incentivising antibacterial research and development. Lancet Infect Dis. 2017;17(8):799–801. Epub 2017/07/07. doi: 10.1016/S1473-3099(17)30404-8 . - DOI - PubMed
    1. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving global targets for antimicrobial resistance. Science. 2016;353(6302):874–5. Epub 2016/08/18. doi: 10.1126/science.aaf9286 . - DOI - PubMed
    1. Singh V, Braddick D, Dhar PK. Exploring the potential of genome editing CRISPR-Cas9 technology. Gene. 2017;599:1–18. Epub 2016/11/09. doi: 10.1016/j.gene.2016.11.008 . - DOI - PubMed
    1. Bikard D, Hatoum-Aslan A, Mucida D, Marraffini LA. CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Cell Host Microbe. 2012;12(2):177–86. doi: 10.1016/j.chom.2012.06.003 . - DOI - PubMed
    1. Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. MBio. 2014;5(1):e00928–13. Epub 2014/01/28. doi: 10.1128/mBio.00928-13 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances